Skip to main content
Top
Published in: Trials 1/2021

Open Access 01-12-2021 | Care | Commentary

Commentary: Pivoting during a pandemic: developing a new recruitment model for a randomised controlled trial in response to COVID-19

Authors: Shakira Milton, Jennifer McIntosh, Lucy Boyd, Napin Karnchanachari, Finlay Macrae, Jon David Emery

Published in: Trials | Issue 1/2021

Login to get access

Abstract

Background

Many non-COVID-19 trials were disrupted in 2020 and either struggled to recruit participants or stopped recruiting altogether. In December 2019, just before the pandemic, we were awarded a grant to conduct a randomised controlled trial, the Should I Take Aspirin? (SITA) trial, in Victoria, the Australian state most heavily affected by COVID-19 during 2020.

Main body

We originally modelled the SITA trial recruitment method on previous trials where participants were approached and recruited in general practice waiting rooms. COVID-19 changed the way general practices worked, with a significant increase in telehealth consultations and restrictions on in person waiting room attendance. This prompted us to adapt our recruitment methods to this new environment to reduce potential risk to participants and staff, whilst minimising any recruitment bias. We designed a novel teletrial model, which involved calling participants prior to their general practitioner appointments to check their eligibility. We delivered the trial both virtually and face-to-face with similar overall recruitment rates to our previous studies.

Conclusion

We developed an effective teletrial model which allowed us to complete recruitment at a high rate. The teletrial model is now being used in our other primary care trials as we continue to face the impacts of the COVID-19 pandemic.
Literature
9.
13.
go back to reference McIntosh JG, Saya S, Minshall J, Bickerstaffe A, Hewabandu N, Qama A, et al. Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care. Br J Gen Pract. 2019;69(689):E836–42 [cited 2021 Jun 7]. Available from: https://pubmed.ncbi.nlm.nih.gov/31636127/.CrossRef McIntosh JG, Saya S, Minshall J, Bickerstaffe A, Hewabandu N, Qama A, et al. Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care. Br J Gen Pract. 2019;69(689):E836–42 [cited 2021 Jun 7]. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​31636127/​.CrossRef
16.
go back to reference Yeung A, Temple-Smith M, Spark S, Guy R, Fairley CK, Law M, et al. Improving chlamydia knowledge should lead to increased chlamydia testing among Australian general practitioners: a cross-sectional study of chlamydia testing uptake in general practice. BMC Infect Dis. 2014;14(1):1–12 [cited 2021 Jun 9]. Available from: http://www.biomedcentral.com/1471-2334/14/584.CrossRef Yeung A, Temple-Smith M, Spark S, Guy R, Fairley CK, Law M, et al. Improving chlamydia knowledge should lead to increased chlamydia testing among Australian general practitioners: a cross-sectional study of chlamydia testing uptake in general practice. BMC Infect Dis. 2014;14(1):1–12 [cited 2021 Jun 9]. Available from: http://​www.​biomedcentral.​com/​1471-2334/​14/​584.CrossRef
18.
go back to reference Zoom Video Communications Inc. Security guide, vol. 2020. San Jose: Zoom Video Communications Inc; 2020. Zoom Video Communications Inc. Security guide, vol. 2020. San Jose: Zoom Video Communications Inc; 2020.
Metadata
Title
Commentary: Pivoting during a pandemic: developing a new recruitment model for a randomised controlled trial in response to COVID-19
Authors
Shakira Milton
Jennifer McIntosh
Lucy Boyd
Napin Karnchanachari
Finlay Macrae
Jon David Emery
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Trials / Issue 1/2021
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-021-05567-0

Other articles of this Issue 1/2021

Trials 1/2021 Go to the issue